Wealthfront Advisers LLC Acquires Shares of 106,055 Haemonetics Co. (NYSE:HAE)

Wealthfront Advisers LLC bought a new position in shares of Haemonetics Co. (NYSE:HAE) during the 4th quarter, HoldingsChannel reports. The firm bought 106,055 shares of the medical instruments supplier’s stock, valued at approximately $7,849,000.

Several other institutional investors have also recently made changes to their positions in HAE. Arizona State Retirement System raised its position in shares of Haemonetics by 1.2% in the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier’s stock worth $1,160,000 after buying an additional 181 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 240 shares during the last quarter. Versor Investments LP grew its stake in shares of Haemonetics by 9.1% during the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock valued at $289,000 after buying an additional 300 shares during the last quarter. Segall Bryant & Hamill LLC grew its stake in shares of Haemonetics by 0.7% during the third quarter. Segall Bryant & Hamill LLC now owns 62,621 shares of the medical instruments supplier’s stock valued at $5,033,000 after buying an additional 407 shares during the last quarter. Finally, Isthmus Partners LLC grew its stake in shares of Haemonetics by 1.1% during the fourth quarter. Isthmus Partners LLC now owns 40,220 shares of the medical instruments supplier’s stock valued at $3,140,000 after buying an additional 450 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Down 3.7 %

HAE opened at $65.77 on Thursday. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The firm has a 50-day simple moving average of $69.15 and a two-hundred day simple moving average of $75.56. The company has a market capitalization of $3.30 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on HAE shares. Barrington Research cut their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. JPMorgan Chase & Co. initiated coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective for the company. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their target price for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Needham & Company LLC reduced their price objective on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.